Kinases as novel therapeutic targets in asthma and chronic obstructive pulmonary disease

Pharmacological Reviews

Volumn 68, Issue 3, 2016, Pages 788-815

  Barnes, Peter J ^a  

^a NATIONAL HEART AND LUNG INSTITUTE   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

APOPTOSIS SIGNAL REGULATING KINASE 1; BRUTON TYROSINE KINASE; BRUTON TYROSINE KINASE INHIBITOR; HEMATOPOIETIC CELL KINASE; I KAPPA B; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; JANUS KINASE INHIBITOR; MAMMALIAN TARGET OF RAPAMYCIN; MAMMALIAN TARGET OF RAPAMYCIN INHIBITOR; MITOGEN ACTIVATED PROTEIN KINASE; MITOGEN ACTIVATED PROTEIN KINASE ACTIVATED PROTEIN KINASE 2; MITOGEN ACTIVATED PROTEIN KINASE INHIBITOR; MITOGEN ACTIVATED PROTEIN KINASE P38; MITOGEN ACTIVATED PROTEIN KINASE P38 INHIBITOR; PHOSPHATIDYLINOSITOL 3 KINASE; PHOSPHATIDYLINOSITOL 3 KINASE INHIBITOR; PROTEIN KINASE; PROTEIN KINASE B; PROTEIN KINASE B INHIBITOR; PROTEIN KINASE C INHIBITOR; PROTEIN KINASE INHIBITOR; PROTEIN KINASE SYK INHIBITOR; PROTEIN TYROSINE KINASE INHIBITOR; RHO KINASE; RHO KINASE INHIBITOR; STEM CELL FACTOR RECEPTOR; STRESS ACTIVATED PROTEIN KINASE INHIBITOR; TRANSFORMING GROWTH FACTOR BETA; UNCLASSIFIED DRUG; ANTIINFLAMMATORY AGENT;

ARTICLE; ASTHMA; CHRONIC OBSTRUCTIVE LUNG DISEASE; CLINICAL TRIAL (TOPIC); DISEASE ASSOCIATION; DRUG TARGETING; ENZYME INHIBITION; HUMAN; NONHUMAN; PATHOGENESIS; PRIORITY JOURNAL; PROTEIN TARGETING; SIGNAL TRANSDUCTION; ENZYMOLOGY; INHALATIONAL DRUG ADMINISTRATION; MOLECULARLY TARGETED THERAPY; PROCEDURES; PULMONARY DISEASE, CHRONIC OBSTRUCTIVE;

ADMINISTRATION, INHALATION; ANTI-INFLAMMATORY AGENTS; ASTHMA; HUMANS; MOLECULAR TARGETED THERAPY; PROTEIN KINASE INHIBITORS; PULMONARY DISEASE, CHRONIC OBSTRUCTIVE;

EID: 84979085064     PISSN: 00316997     EISSN: 15210081     Source Type: Journal    
DOI: 10.1124/pr.116.012518     Document Type: Article

References (336)

1. Abraham SM, Lawrence T, Kleiman A, Warden P, Medghalchi M, Tuckermann J, Saklatvala J, and Clark AR (2006) Antiinflammatory effects of dexamethasone are partly dependent on induction of dual specificity phosphatase 1. J Exp Med 203: 1883-1889.
2. Adcock IM, Chung KF, Caramori G, and Ito K (2006) Kinase inhibitors and airway inflammation. Eur J Pharmacol 533:118-132.
3. Adcock IM, Lane SJ, Brown CR, Lee TH, and Barnes PJ (1995) Abnormal glucocorticoid receptor-activator protein 1 interaction in steroid-resistant asthma. J Exp Med 182:1951-1958.
4. Ajibade AA, Wang HY, and Wang RF (2013) Cell type-specific function of TAK1 in innate immune signaling. Trends Immunol 34:307-316.
5. Alexander W (2011) Inhibiting the akt pathway in cancer treatment: three leading candidates. P&T 36:225-227.
6. Ali K, Camps M, Pearce WP, Ji H, Rückle T, Kuehn N, Pasquali C, Chabert C, Rommel C, and Vanhaesebroeck B (2008) Isoform-specific functions of phosphoinositide 3-kinases: p110 d but not p110 g promotes optimal allergic responses in vivo. J Immunol 180:2538-2544.
7. Ameriks MK and Venable JD (2009) Small molecule inhibitors of phosphoinositide 3-kinase (PI3K) delta and gamma. Curr Top Med Chem 9:738-753.
8. Anderson DR, Meyers MJ, Kurumbail RG, Caspers N, Poda GI, Long SA, Pierce BS, Mahoney MW, and Mourey RJ (2009) Benzothiophene inhibitors of MK2. Part 1: structure-activity relationships, assessments of selectivity and cellular potency. Bioorg Med Chem Lett 19:4878-4881.
9. Arthur JS and Ley SC (2013) Mitogen-activated protein kinases in innate immunity. Nat Rev Immunol 13:679-692.
10. Aschner Y and Downey GP (2016) Transforming growth factor-b: Master regulator of the respiratory system in health and disease. Am J Respir Cell Mol Biol 54: 647-655.
11. Ashino S, Takeda K, Li H, Taylor V, Joetham A, Pine PR, and Gelfand EW (2014) Janus kinase 1/3 signaling pathways are key initiators of TH2 differentiation and lung allergic responses. J Allergy Clin Immunol 133:1162-1174.
12. Backers K, Blero D, Paternotte N, Zhang J, and Erneux C (2003) The termination of PI3K signalling by SHIP1 and SHIP2 inositol 5-phosphatases. Adv Enzyme Regul 43:15-28.
13. Balzar S, Chu HW, Silkoff P, Cundall M, Trudeau JB, Strand M, and Wenzel S (2005) Increased TGF-beta2 in severe asthma with eosinophilia. J Allergy Clin Immunol 115:110-117.
14. Barnes PJ (2008a) The cytokine network in asthma and chronic obstructive pulmonary disease. J Clin Invest 118:3546-3556.
15. Barnes PJ (2008b) Immunology of asthma and chronic obstructive pulmonary disease. Nat Rev Immunol 8:183-192.
16. Barnes PJ (2011) Pathophysiology of allergic inflammation. Immunol Rev 242:31-50.
17. Barnes PJ (2013a) Corticosteroid resistance in patients with asthma and chronic obstructive pulmonary disease. J Allergy Clin Immunol 131:636-645.
18. Barnes PJ (2013b) New anti-inflammatory targets for chronic obstructive pulmonary disease. Nat Rev Drug Discov 12:543-559.
19. Barnes PJ (2013c) Theophylline. Am J Respir Crit Care Med 188:901-906.
20. Barnes PJ (2015a) Mechanisms of development of multimorbidity in the elderly. Eur Respir J 45:790-806.
21. Barnes PJ (2015b) Therapeutic approaches to asthma-chronic obstructive pulmonary disease overlap syndromes. J Allergy Clin Immunol 136:531-545.
22. Barnes PJ (2016) Asthma-COPD overlap. Chest 149:7-8.
23. Barnes PJ and Adcock IM (2009) Glucocorticoid resistance in inflammatory diseases. Lancet 373:1905-1917.
24. Barnes PJ, Burney PGJ, Silverman EK, Celli BR, Vestbo J, Wedzicha JA, and Wouters EFM (2015) Chronic obstructive pulmonary disease. Nat Rev Dis Primers 1:15076.
25. Barnes PJ and Karin M (1997) Nuclear factor-kappaB: a pivotal transcription factor in chronic inflammatory diseases. N Engl J Med 336:1066-1071.
26. Barouch-Bentov R and Sauer K (2011) Mechanisms of drug resistance in kinases. Expert Opin Investig Drugs 20:153-208.
27. Bateman ED, Reddel HK, van Zyl-Smit RN, and Agusti A (2015) The asthma-COPD overlap syndrome: towards a revised taxonomy of chronic airways diseases? Lancet Respir Med 3:719-728.
28. Beasley R, Crane J, Lai CK, and Pearce N (2000) Prevalence and etiology of asthma. J Allergy Clin Immunol 105:S466-S472.
29. Bentley JK, Newcomb DC, Goldsmith AM, Jia Y, Sajjan US, and Hershenson MB (2007) Rhinovirus activates interleukin-8 expression via a Src/p110b phosphatidylinositol 3-kinase/Akt pathway in human airway epithelial cells. J Virol 81: 1186-1194.
30. Berlin AA and Lukacs NW (2005) Treatment of cockroach allergen asthma model with imatinib attenuates airway responses. Am J Respir Crit Care Med 171:35-39.
31. Bhavsar P, Hew M, Khorasani N, Torrego A, Barnes PJ, Adcock I, and Chung KF (2008) Relative corticosteroid insensitivity of alveolar macrophages in severe asthma compared with non-severe asthma. Thorax 63:784-790.
32. Birrell MA, Wong S, Hardaker EL, Catley MC, McCluskie K, Collins M, Haj-Yahia S, and Belvisi MG (2006) IkappaB kinase-2-independent and-dependent inflammation in airway disease models: relevance of IKK-2 inhibition to the clinic. Mol Pharmacol 69:1791-1800.
33. Bossé Y and Rola-Pleszczynski M (2008) FGF2 in asthmatic airway-smooth-musclecell hyperplasia. Trends Mol Med 14:3-11.
34. Braido F, Brusselle G, Ingrassia E, Nicolini G, Price D, Roche N, Soriano JB, and Worth H; LIAISON study group (2013) InternationaL cross-sectIonAl and longItudinal assessment on aSthma cONtrol in European adult patients-the LIAISON study protocol. BMC Pulm Med 13:18.
35. Brook M, Tchen CR, Santalucia T, McIlrath J, Arthur JS, Saklatvala J, and Clark AR (2006) Posttranslational regulation of tristetraprolin subcellular localization and protein stability by p38 mitogen-activated protein kinase and extracellular signalregulated kinase pathways. Mol Cell Biol 26:2408-2418.
36. Brown JR (2015) Idelalisib has CLL on the run! Blood 126:2656-2657.
37. Caramori G, Oates T, Nicholson AG, Casolari P, Ito K, Barnes PJ, Papi A, Adcock IM, and Chung KF (2009) Activation of NF-kappaB transcription factor in asthma death. Histopathology 54:507-509.
38. Caramori G, Romagnoli M, Casolari P, Bellettato C, Casoni G, Boschetto P, Chung KF, Barnes PJ, Adcock IM, and Ciaccia A, et al. (2003) Nuclear localisation of p65 in sputum macrophages but not in sputum neutrophils during COPD exacerbations. Thorax 58:348-351.
39. Carlin S, Poronnik P, Cook DI, Carpenter L, Biden TJ, Johnson PR, and Black JL (2000) An antisense of protein kinase C-zeta inhibits proliferation of human airway smooth muscle cells. Am J Respir Cell Mol Biol 23:555-559.
40. Carracedo A and Pandolfi PP (2008) The PTEN-PI3K pathway: of feedbacks and cross-talks. Oncogene 27:5527-5541.
41. Catley MC, Sukkar MB, Chung KF, Jaffee B, Liao SM, Coyle AJ, Haddad B, Barnes PJ, and Newton R (2006) Validation of the anti-inflammatory properties of smallmolecule IkappaB Kinase (IKK)-2 inhibitors by comparison with adenoviralmediated delivery of dominant-negative IKK1 and IKK2 in human airways smooth muscle. Mol Pharmacol 70:697-705.
42. Chand S, Mehta N, Bahia MS, Dixit A, and Silakari O (2012) Protein kinase C-theta inhibitors: a novel therapy for inflammatory disorders. Curr Pharm Des 18: 4725-4746.
43. Chaudhary D, Robinson S, and Romero DL (2015) Recent advances in the discovery of small molecule inhibitors of interleukin-1 receptor-associated kinase 4 (IRAK4) as a therapeutic target for inflammation and oncology disorders. J Med Chem 58: 96-110.
44. Chiarini F, Evangelisti C, McCubrey JA, and Martelli AM (2015) Current treatment strategies for inhibiting mTOR in cancer. Trends Pharmacol Sci 36:124-135.
45. Cho SH, Woo CH, Yoon SB, and Kim JH (2004a) Protein kinase Cdelta functions downstream of Ca2+ mobilization in FcepsilonRI signaling to degranulation in mast cells. J Allergy Clin Immunol 114:1085-1092.
46. Cho SH, You HJ, Woo CH, Yoo YJ, and Kim JH (2004b) Rac and protein kinase C-delta regulate ERKs and cytosolic phospholipase A2 in FcepsilonRI signaling to cysteinyl leukotriene synthesis in mast cells. J Immunol 173:624-631.
47. Choi YH, Jin GY, Li LC, and Yan GH (2013) Inhibition of protein kinase C delta attenuates allergic airway inflammation through suppression of PI3K/Akt/mTOR/ HIF-1 alpha/VEGF pathway. PLoS One 8:e81773.
48. Chung KF (2011) p38 mitogen-activated protein kinase pathways in asthma and COPD. Chest 139:1470-1479.
49. Chung S, Sundar IK, Hwang JW, Yull FE, Blackwell TS, Kinnula VL, Bulger M, Yao H, and Rahman I (2011) NF-kB inducing kinase, NIK mediates cigarette smoke/ TNFa-induced histone acetylation and inflammation through differential activation of IKKs. PLoS One 6:e23488.
50. Chung KF and Wenzel S; European Respiratory Society/American Thoracic Society Severe Asthma International Guidelines Task Force (2014) From the authors: International European Respiratory Society/American Thoracic Society guidelines on severe asthma. Eur Respir J 44:1378-1379.
51. Cohen P (2002) Protein kinases-the major drug targets of the twenty-first century? Nat Rev Drug Discov 1:309-315.
52. Cohen P (2014) Immune diseases caused by mutations in kinases and components of the ubiquitin system. Nat Immunol 15:521-529.
53. Comess KM, Sun C, Abad-Zapatero C, Goedken ER, Gum RJ, Borhani DW, Argiriadi M, Groebe DR, Jia Y, and Clampit JE, et al. (2011) Discovery and characterization of non-ATP site inhibitors of the mitogen activated protein (MAP) kinases. ACS Chem Biol 6:234-244.
54. Condliffe AM, Davidson K, Anderson KE, Ellson CD, Crabbe T, Okkenhaug K, Vanhaesebroeck B, Turner M, Webb L, and Wymann MP, et al. (2005) Sequential activation of class IB and class IA PI3K is important for the primed respiratory burst of human but not murine neutrophils. Blood 106:1432-1440.
55. Cosio BG, Tsaprouni L, Ito K, Jazrawi E, Adcock IM, and Barnes PJ (2004) Theophylline restores histone deacetylase activity and steroid responses in COPD macrophages. J Exp Med 200:689-695.
56. Costa C, Martin-Conte EL, and Hirsch E (2011) Phosphoinositide 3-kinase p110g in immunity. IUBMB Life 63:707-713.
57. Costa C, Rufino R, Traves SL, Lapa E Silva JR, Barnes PJ, and Donnelly LE (2008) CXCR3 and CCR5 chemokines in induced sputum from patients with COPD. Chest 133:26-33.
58. Crofford LJ, Nyhoff LE, Sheehan JH, and Kendall PL (2016) The role of Bruton’s tyrosine kinase in autoimmunity and implications for therapy. Expert Rev Clin Immunol 4:1-11.
59. DaCosta Byfield S, Major C, Laping NJ, and Roberts AB (2004) SB-505124 is a selective inhibitor of transforming growth factor-b type I receptors ALK4, ALK5, and ALK7. Mol Pharmacol 65:744-752.
60. Dallas SL, Rosser JL, Mundy GR, and Bonewald LF (2002) Proteolysis of latent transforming growth factor-b (TGF-b)-binding protein-1 by osteoclasts. A cellular mechanism for release of TGF-b from bone matrix. J Biol Chem 277:21352-21360.
61. Dean JL, Sully G, Clark AR, and Saklatvala J (2004) The involvement of AU-rich element-binding proteins in p38 mitogen-activated protein kinase pathwaymediated mRNA stabilisation. Cell Signal 16:1113-1121.
62. de Boer WI, Hau CM, van Schadewijk A, Stolk J, van Krieken JH, and Hiemstra PS (2006) Expression of epidermal growth factors and their receptors in the bronchial epithelium of subjects with chronic obstructive pulmonary disease. Am J Clin Pathol 125:184-192.
63. de Boer WI, van Schadewijk A, Sont JK, Sharma HS, Stolk J, Hiemstra PS, and van Krieken JH (1998) Transforming growth factor beta1 and recruitment of macrophages and mast cells in airways in chronic obstructive pulmonary disease. Am J Respir Crit Care Med 158:1951-1957.
64. Dempsey EC, Cool CD, and Littler CM (2007) Lung disease and PKCs. Pharmacol Res 55:545-559.
65. Desmet C, Gosset P, Pajak B, Cataldo D, Bentires-Alj M, Lekeux P, and Bureau F (2004) Selective blockade of NF-kappa B activity in airway immune cells inhibits the effector phase of experimental asthma. J Immunol 173:5766-5775.
66. Devereux G, Cotton S, Barnes P, Briggs A, Burns G, Chaudhuri R, Chrystyn H, Davies L, De Soyza A, and Fielding S, et al. (2015) Use of low-dose oral theophylline as an adjunct to inhaled corticosteroids in preventing exacerbations of chronic obstructive pulmonary disease: study protocol for a randomised controlled trial. Trials 16:267.
67. Dienstmann R, Rodon J, Serra V, and Tabernero J (2014) Picking the point of inhibition: a comparative review of PI3K/AKT/mTOR pathway inhibitors. Mol Cancer Ther 13:1021-1031.
68. Di Stefano A, Caramori G, Capelli A, Gnemmi I, Ricciardolo FL, Oates T, Donner CF, Chung KF, Barnes PJ, and Adcock IM (2004) STAT4 activation in smokers and patients with chronic obstructive pulmonary disease. Eur Respir J 24:78-85.
69. Di Stefano A, Caramori G, Oates T, Capelli A, Lusuardi M, Gnemmi I, Ioli F, Chung KF, Donner CF, and Barnes PJ, et al. (2002) Increased expression of nuclear factorkappaB in bronchial biopsies from smokers and patients with COPD. Eur Respir J 20:556-563.
70. Dong T, Li C, Wang X, Dian L, Zhang X, Li L, Chen S, Cao R, Li L, and Huang N, et al. (2015) Ainsliadimer A selectively inhibits IKKa/b by covalently binding a conserved cysteine. Nat Commun 6:6522.
71. Donnelly LE, Newton R, Kennedy GE, Fenwick PS, Leung RH, Ito K, Russell RE, and Barnes PJ (2004) Anti-inflammatory effects of resveratrol in lung epithelial cells: molecular mechanisms. Am J Physiol Lung Cell Mol Physiol 287: L774-L783.
72. Donnelly R, Yang K, Omary MB, Azhar S, and Black JL (1995) Expression of multiple isoenzymes of protein kinase C in airway smooth muscle. Am J Respir Cell Mol Biol 13:253-256.
73. Doukas J, Eide L, Stebbins K, Racanelli-Layton A, Dellamary L, Martin M, Dneprovskaia E, Noronha G, Soll R, and Wrasidlo W, et al. (2009) Aerosolized phosphoinositide 3-kinase gamma/delta inhibitor TG100-115[3-[2,4-diamino-6-(3-hydroxyphenyl)pteridin-7-yl]phenol] as a therapeutic candidate for asthma and chronic obstructive pulmonary disease. J Pharmacol Exp Ther 328:758-765.
74. Duan W, Aguinaldo Datiles AM, Leung BP, Vlahos CJ, and Wong WS (2005a) An anti-inflammatory role for a phosphoinositide 3-kinase inhibitor LY294002 in a mouse asthma model. Int Immunopharmacol 5:495-502.
75. Duan W, Chan JH, McKay K, Crosby JR, Choo HH, Leung BP, Karras JG, and Wong WS (2005b) Inhaled p38alpha mitogen-activated protein kinase antisense oligonucleotide attenuates asthma in mice. Am J Respir Crit Care Med 171:571-578.
76. Ernst M, Inglese M, Scholz GM, Harder KW, Clay FJ, and Bozinovski S, et al. (2002) Constitutive activation of the SRC family kinase Hck results in spontaneous pulmonary inflammation and an enhanced innate immune response. J Exp Med 196: 589-604.
77. Evans DJ, Lindsay MA, Webb BL, Kankaanranta H, Giembycz MA, O’Connor BJ, and Barnes PJ (1999) Expression and activation of protein kinase C-zeta in eosinophils after allergen challenge. Am J Physiol 277:L233-L239.
78. Eynott PR, Nath P, Leung SY, Adcock IM, Bennett BL, and Chung KF (2003) Allergen-induced inflammation and airway epithelial and smooth muscle cell proliferation: role of Jun N-terminal kinase. Br J Pharmacol 140:1373-1380.
79. Fabbro D, Cowan-Jacob SW, and Moebitz H (2015) Ten things you should know about protein kinases: IUPHAR Review 14. Br J Pharmacol 172: 2675-2700.
80. Feltis BN, Wignarajah D, Zheng L, Ward C, Reid D, Harding R, and Walters EH (2006) Increased vascular endothelial growth factor and receptors: relationship to angiogenesis in asthma. Am J Respir Crit Care Med 173:1201-1207.
81. Fenwick PS, Macedo P, Kilty IC, Barnes PJ, and Donnelly LE (2015) Effect of JAK inhibitors on release of CXCL9, CXCL10 and CXCL11 from human airway epithelial cells. PLoS One 10:e0128757.
82. Fenwick P, Rao V, Kilty I, Lee K, Barnes PJ, and Donnelly D (2013) Inhibition of IRAK4 suppresses chemokine release from human bronchial epithelial cells. Eur Respir J 44:1033s
83. Fernandes LB, Henry PJ, and Goldie RG (2007) Rho kinase as a therapeutic target in the treatment of asthma and chronic obstructive pulmonary disease. Ther Adv Respir Dis 1:25-33.
84. Fiore M, Forli S, and Manetti F (2016) Targeting mitogen-activated protein kinaseactivated protein kinase 2 (MAPKAPK2, MK2): medicinal chemistry efforts to lead small molecule inhibitors to clinical trials. J Med Chem 59:3609-3634.
85. Firestein R, Blander G, Michan S, Oberdoerffer P, Ogino S, Campbell J, Bhimavarapu A, Luikenhuis S, de Cabo R, and Fuchs C, et al. (2008) The SIRT1 deacetylase suppresses intestinal tumorigenesis and colon cancer growth. PLoS One 3:e2020.
86. Foluso O, Glick A, Stender M, and Jaiyesimi I (2016) Ibrutinib as a bruton kinase inhibitor in the management of chronic lymphocytic leukemia: a new agent with great promise. Clin Lymphoma Myeloma Leuk 16:63-69.
87. Footitt J, Mallia P, Durham AL, Ho WE, Trujillo-Torralbo MB, Telcian AG, Del Rosario A, Chang C, Peh HY, and Kebadze T, et al. (2016) Oxidative and nitrosative stress and histone deacetylase-2 activity in exacerbations of COPD. Chest 149:62-73.
88. Frémin C and Meloche S (2010) From basic research to clinical development of MEK1/2 inhibitors for cancer therapy. J Hematol Oncol 3:8.
89. Gaestel M (2013) What goes up must come down: molecular basis of MAPKAP kinase 2/3-dependent regulation of the inflammatory response and its inhibition. Biol Chem 394:1301-1315.
90. Gaffey K, Reynolds S, Plumb J, Kaur M, and Singh D (2013) Increased phosphorylated p38 mitogen-activated protein kinase in COPD lungs. Eur Respir J 42:28-41.
91. Galli SJ and Tsai M (2012) IgE and mast cells in allergic disease. Nat Med 18: 693-704.
92. Garuti L, Roberti M, and Bottegoni G (2015) Multi-kinase inhibitors. Curr Med Chem 22:695-712.
93. Geahlen RL (2014) Getting Syk: spleen tyrosine kinase as a therapeutic target. Trends Pharmacol Sci 35:414-422.
94. Ghoreschi K, Laurence A, and O’Shea JJ (2009) Janus kinases in immune cell signaling. Immunol Rev 228:273-287.
95. Goldsmith AM, Bentley JK, Zhou L, Jia Y, Bitar KN, Fingar DC, and Hershenson MB (2006) Transforming growth factor-beta induces airway smooth muscle hypertrophy. Am J Respir Cell Mol Biol 34:247-254.
96. Göransson O, McBride A, Hawley SA, Ross FA, Shpiro N, Foretz M, Viollet B, Hardie DG, and Sakamoto K (2007) Mechanism of action of A-769662, a valuable tool for activation of AMP-activated protein kinase. J Biol Chem 282:32549-32560.
97. Gorska MM, Liang Q, Stafford SJ, Goplen N, Dharajiya N, Guo L, Sur S, Gaestel M, and Alam R (2007) MK2 controls the level of negative feedback in the NF-kappaB pathway and is essential for vascular permeability and airway inflammation. J Exp Med 204:1637-1652.
98. Gosens R, Schaafsma D, Meurs H, Zaagsma J, and Nelemans SA (2004) Role of Rhokinase in maintaining airway smooth muscle contractile phenotype. Eur J Pharmacol 483:71-78.
99. Grandordy BM, Mak JCW, and Barnes PJ (1994) Modulation of airway smooth muscle b-adrenoceptor function by a muscarinic agonist. Life Sci 54:185-191.
100. Griego SD, Weston CB, Adams JL, Tal-Singer R, and Dillon SB (2000) Role of p38 mitogen-activated protein kinase in rhinovirus-induced cytokine production by bronchial epithelial cells. J Immunol 165:5211-5220.
101. Guyer BJ, Shimamoto SR, Bradhurst AL, Grossbard EB, Dreskin SC, and Nelson HS (2006) Mast cell inhibitor R112 is well tolerated and affects prostaglandin D2 but not other mediators, symptoms, or nasal volumes in a nasal challenge model of allergic rhinitis. Allergy Asthma Proc 27:208-213.
102. Halayko AJ, Kartha S, Stelmack GL, McConville J, Tam J, Camoretti-Mercado B, Forsythe SM, Hershenson MB, and Solway J (2004) Phophatidylinositol-3 kinase/ mammalian target of rapamycin/p70S6K regulates contractile protein accumulation in airway myocyte differentiation. Am J Respir Cell Mol Biol 31:266-275.
103. Hall DJ, Bates ME, Guar L, Cronan M, Korpi N, and Bertics PJ (2005) The role of p38 MAPK in rhinovirus-induced monocyte chemoattractant protein-1 production by monocytic-lineage cells. J Immunol 174:8056-8063.
104. Halwani R, Al-Muhsen S, Al-Jahdali H, and Hamid Q (2011) Role of transforming growth factor-b in airway remodeling in asthma. Am J Respir Cell Mol Biol 44: 127-133.
105. Hamilton LM, Torres-Lozano C, Puddicombe SM, Richter A, Kimber I, Dearman RJ, Vrugt B, Aalbers R, Holgate ST, and Djukanović R, et al. (2003) The role of the epidermal growth factor receptor in sustaining neutrophil inflammation in severe asthma. Clin Exp Allergy 33:233-240.
106. Hardyman MA, Wilkinson E, Martin E, Jayasekera NP, Blume C, Swindle EJ, Gozzard N, Holgate ST, Howarth PH, and Davies DE, et al. (2013) TNF-a-mediated bronchial barrier disruption and regulation by src-family kinase activation. J Allergy Clin Immunol 132:665-675.
107. Hart L, Lim S, Adcock I, Barnes PJ, and Chung KF (2000) Effects of inhaled corticosteroid therapy on expression and DNA-binding activity of nuclear factor kappaB in asthma. Am J Respir Crit Care Med 161:224-231.
108. Hart LA, Krishnan VL, Adcock IM, Barnes PJ, and Chung KF (1998) Activation and localization of transcription factor, nuclear factor-kappaB, in asthma. Am J Respir Crit Care Med 158:1585-1592.
109. Hatcher H, Planalp R, Cho J, Torti FM, and Torti SV (2008) Curcumin: from ancient medicine to current clinical trials. Cell Mol Life Sci 65:1631-1652.
110. Hattori K, Naguro I, Runchel C, and Ichijo H (2009) The roles of ASK family proteins in stress responses and diseases. Cell Commun Signal 7:9.
111. Hawkins PT and Stephens LR (2015) PI3K signalling in inflammation. Biochim Biophys Acta 1851:882-897.
112. Hayden MS and Ghosh S (2012) NF-kB, the first quarter-century: remarkable progress and outstanding questions. Genes Dev 26:203-234.
113. Hegab AE, Sakamoto T, Nomura A, Ishii Y, Morishima Y, Iizuka T, Kiwamoto T, Matsuno Y, Homma S, and Sekizawa K (2007) Niflumic acid and AG-1478 reduce cigarette smoke-induced mucin synthesis: the role of hCLCA1. Chest 131: 1149-1156.
114. Hekking PP, Wener RR, Amelink M, Zwinderman AH, Bouvy ML, and Bel EH (2015) The prevalence of severe refractory asthma. J Allergy Clin Immunol 135:896-902.
115. Henry PJ, Mann TS, and Goldie RG (2005) A rho kinase inhibitor, Y-27632 inhibits pulmonary eosinophilia, bronchoconstriction and airways hyperresponsiveness in allergic mice. Pulm Pharmacol Ther 18:67-74.
116. Herbertz S, Sawyer JS, Stauber AJ, Gueorguieva I, Driscoll KE, Estrem ST, Cleverly AL, Desaiah D, Guba SC, and Benhadji KA, et al. (2015) Clinical development of galunisertib (LY2157299 monohydrate), a small molecule inhibitor of transforming growth factor-beta signaling pathway. Drug Des Devel Ther 9:4479-4499.
117. Hirota JA, Ask K, Farkas L, Smith JA, Ellis R, Rodriguez-Lecompte JC, Kolb M, and Inman MD (2011) In vivo role of platelet-derived growth factor-BB in airway smooth muscle proliferation in mouse lung. Am J Respir Cell Mol Biol 45:566-572.
118. Hirst SJ, Barnes PJ, and Twort CHC (1996) PDGF isoform-induced proliferation and receptor expression in human cultured airway smooth muscle cells. Am J Physiol 270:L415-L428.
119. Hoshino M, Takahashi M, and Aoike N (2001) Expression of vascular endothelial growth factor, basic fibroblast growth factor, and angiogenin immunoreactivity in asthmatic airways and its relationship to angiogenesis. J Allergy Clin Immunol 107:295-301.
120. Hua W, Liu H, Xia LX, Tian BP, Huang HQ, Chen ZY, Ju ZY, Li W, Chen ZH, and Shen HH (2015) Rapamycin inhibition of eosinophil differentiation attenuates allergic airway inflammation in mice. Respirology 20:1055-1065.
121. Hubbard SR and Till JH (2000) Protein tyrosine kinase structure and function. Annu Rev Biochem 69:373-398.
122. Humbert M, de Blay F, Garcia G, Prud’homme A, Leroyer C, Magnan A, Tunonde-Lara JM, Pison C, Aubier M, and Charpin D, et al. (2009) Masitinib, a c-kit/ PDGF receptor tyrosine kinase inhibitor, improves disease control in severe corticosteroid-dependent asthmatics. Allergy 64:1194-1201.
123. Ichiyama T, Hasegawa S, Matsubara T, Hayashi T, and Furukawa S (2001) Theophylline inhibits NF-k B activation and I k B a degradation in human pulmonary epithelial cells. Naunyn Schmiedebergs Arch Pharmacol 364:558-561.
124. Ihn H (2002) Pathogenesis of fibrosis: role of TGF-b and CTGF. Curr Opin Rheumatol 14:681-685.
125. Irusen E, Matthews JG, Takahashi A, Barnes PJ, Chung KF, and Adcock IM (2002) p38 Mitogen-activated protein kinase-induced glucocorticoid receptor phosphorylation reduces its activity: role in steroid-insensitive asthma. J Allergy Clin Immunol 109:649-657.
126. Ito K, Caramori G, and Adcock IM (2007) Therapeutic potential of phosphatidylinositol 3-kinase inhibitors in inflammatory respiratory disease. J Pharmacol Exp Ther 321:1-8.
127. Ito K, Lim S, Caramori G, Cosio B, Chung KF, Adcock IM, and Barnes PJ (2002) A molecular mechanism of action of theophylline: Induction of histone deacetylase activity to decrease inflammatory gene expression. Proc Natl Acad Sci USA 99: 8921-8926.
128. Jabara HH and Geha RS (2005) Jun N-terminal kinase is essential for CD40-mediated IgE class switching in B cells. J Allergy Clin Immunol 115:856-863.
129. Joh EH and Kim DH (2010) Lancemaside A inhibits lipopolysaccharide-induced inflammation by targeting LPS/TLR4 complex. J Cell Biochem 111:865-871.
130. Johnson GL and Lapadat R (2002) Mitogen-activated protein kinase pathways mediated by ERK, JNK, and p38 protein kinases. Science 298:1911-1912.
131. Johnson SC, Rabinovitch PS, and Kaeberlein M (2013) mTOR is a key modulator of ageing and age-related disease. Nature 493:338-345.
132. Jun JI and Lau LF (2011) Taking aim at the extracellular matrix: CCN proteins as emerging therapeutic targets. Nat Rev Drug Discov 10:945-963.
133. Kanazawa HTY, Asai K, and Hirata K (2014) Simultaneous assessment of hepatocyte growth factor and vascular endothelial growth factor in epithelial lining fluid from patients with COPD. Chest 146:1159-1165.
134. Kanazawa H, Asai K, Hirata K, and Yoshikawa J (2003) Possible effects of vascular endothelial growth factor in the pathogenesis of chronic obstructive pulmonary disease. Am J Med 114:354-358.
135. Kankaanranta H, De Souza PM, Barnes PJ, Salmon M, Giembycz MA, and Lindsay MA (1999) SB 203580, an inhibitor of p38 mitogen-activated protein kinase, enhances constitutive apoptosis of cytokine-deprived human eosinophils. J Pharmacol Exp Ther 290:621-628.
136. Kankaanranta H, Ilmarinen P, Zhang X, Adcock IM, Lahti A, Barnes PJ, Giembycz MA, Lindsay MA, and Moilanen E (2014) Tumour necrosis factor-a regulates human eosinophil apoptosis via ligation of TNF-receptor 1 and balance between NF-kB and AP-1. PLoS One 9:e90298.
137. Kasahara DI, Mathews JA, Park CY, Cho Y, Hunt G, Wurmbrand AP, Liao JK, and Shore SA (2015) ROCK insufficiency attenuates ozone-induced airway hyperresponsiveness in mice. Am J Physiol Lung Cell Mol Physiol 309:L736-L746.
138. Keating GM (2015) Nintedanib: A review of its use in patients with idiopathic pulmonary fibrosis. Drugs 75:1131-1140.
139. Khorasani N, Baker J, Johnson M, Chung KF, and Bhavsar PK (2015) Reversal of corticosteroid insensitivity by p38 MAPK inhibition in peripheral blood mononuclear cells from COPD. Int J Chron Obstruct Pulmon Dis 10:283-291.
140. Kilty I and Jones LH (2015) TAK1 selective inhibition: state of the art and future opportunities. Future Med Chem 7:23-33.
141. Kim DH, Jung WS, Kim ME, Lee HW, Youn HY, Seon JK, Lee HN, and Lee JS (2014) Genistein inhibits pro‑inflammatory cytokines in human mast cell activation through the inhibition of the ERK pathway. Int J Mol Med 34:1669-1674.
142. Kim BS, Kim IK, Park YJ, Kim YS, Kim YJ, Chang WS, Lee YS, Kweon MN, Chung Y, and Kang CY (2010) Conversion of Th2 memory cells into Foxp3+ regulatory T cells suppressing Th2-mediated allergic asthma. Proc Natl Acad Sci USA 107: 8742-8747.
143. Kim MS, Rådinger M, and Gilfillan AM (2008) The multiple roles of phosphoinositide 3-kinase in mast cell biology. Trends Immunol 29:493-501.
144. Knipe RS, Tager AM, and Liao JK (2015) The Rho kinases: critical mediators of multiple profibrotic processes and rational targets for new therapies for pulmonary fibrosis. Pharmacol Rev 67:103-117.
145. Kobayashi Y, Mercado N, Miller-Larsson A, Barnes PJ, and Ito K (2012) Increased corticosteroid sensitivity by a long acting b2 agonist formoterol via b2 adrenoceptor independent protein phosphatase 2A activation. Pulm Pharmacol Ther 25: 201-207.
146. Kobayashi Y, Wada H, Rossios C, Takagi D, Charron C, Barnes PJ, and Ito K (2013) A novel macrolide/fluoroketolide, solithromycin (CEM-101), reverses corticosteroid insensitivity via phosphoinositide 3-kinase pathway inhibition. Br J Pharmacol 169:1024-1034.
147. Koch A, Giembycz M, Ito K, Lim S, Jazrawi E, Barnes PJ, Adcock I, Erdmann E, and Chung KF (2004) Mitogen-activated protein kinase modulation of nuclear factor-kappaB-induced granulocyte macrophage-colony-stimulating factor release from human alveolar macrophages. Am J Respir Cell Mol Biol 30: 342-349.
148. Koh RY, Lim CL, Uhal BD, Abdullah M, Vidyadaran S, Ho CC, and Seow HF (2015) Inhibition of transforming growth factor-b via the activin receptor-like kinase-5 inhibitor attenuates pulmonary fibrosis. Mol Med Rep 11:3808-3813.
149. Kokturk N, Tatlicioglu T, Memis L, Akyurek N, and Akyol G (2003) Expression of transforming growth factor beta1 in bronchial biopsies in asthma and COPD. J Asthma 40:887-893.
150. Koli K, Myllärniemi M, Keski-Oja J, and Kinnula VL (2008) Transforming growth factor-beta activation in the lung: focus on fibrosis and reactive oxygen species. Antioxid Redox Signal 10:333-342.
151. Kono Y, Nishiuma T, Okada T, Kobayashi K, Funada Y, Kotani Y, Jahangeer S, Nakamura S, and Nishimura Y (2010) Sphingosine kinase 1 regulates mucin production via ERK phosphorylation. Pulm Pharmacol Ther 23:36-42.
152. Kontzias A, Kotlyar A, Laurence A, Changelian P, and O’Shea JJ (2012) Jakinibs: a new class of kinase inhibitors in cancer and autoimmune disease. Curr Opin Pharmacol 12:464-470.
153. Kudlacz E, Conklyn M, Andresen C, Whitney-Pickett C, and Changelian P (2008) The JAK-3 inhibitor CP-690550 is a potent anti-inflammatory agent in a murine model of pulmonary eosinophilia. Eur J Pharmacol 582:154-161.
154. Lamming DW, Ye L, Sabatini DM, and Baur JA (2013) Rapalogs and mTOR inhibitors as anti-aging therapeutics. J Clin Invest 123:980-989.
155. Lane SJ, Adcock IM, Richards D, Hawrylowicz C, Barnes PJ, and Lee TH (1998) Corticosteroid-resistant bronchial asthma is associated with increased c-fos expression in monocytes and T lymphocytes. J Clin Invest 102:2156-2164.
156. Langlois A, Chouinard F, Flamand N, Ferland C, Rola-Pleszczynski M, and Laviolette M (2009) Crucial implication of protein kinase C (PKC)-delta, PKCzeta, ERK-1/2, and p38 MAPK in migration of human asthmatic eosinophils. J Leukoc Biol 85:656-663.
157. Laping NJ, Grygielko E, Mathur A, Butter S, Bomberger J, Tweed C, Martin W, Fornwald J, Lehr R, and Harling J, et al. (2002) Inhibition of transforming growth factor (TGF)-beta1-induced extracellular matrix with a novel inhibitor of the TGFbeta type I receptor kinase activity: SB-431542. Mol Pharmacol 62:58-64.
158. Lau C, Castellanos P, Ranev D, Wang X, and Chow CW (2011) HRV signaling in airway epithelial cells is regulated by ITAM-mediated recruitment and activation of Syk. Protein Pept Lett 18:518-529.
159. Lau C, Wang X, Song L, North M, Wiehler S, Proud D, and Chow CW (2008) Syk associates with clathrin and mediates phosphatidylinositol 3-kinase activation during human rhinovirus internalization. J Immunol 180:870-880.
160. Leaker BR, Barnes PJ, O’Connor BJ, Ali FY, Tam P, Neville J, Mackenzie LF, and MacRury T (2014) The effects of the novel SHIP1 activator AQX-1125 on allergen-induced responses in mild-to-moderate asthma. Clin Exp Allergy 44: 1146-1153.
161. Lee YC, Chuang CY, Lee PK, Lee JS, Harper RW, Buckpitt AB, Wu R, and Oslund K (2008) TRX-ASK1-JNK signaling regulation of cell density-dependent cytotoxicity in cigarette smoke-exposed human bronchial epithelial cells. Am J Physiol Lung Cell Mol Physiol 294:L921-L931.
162. Lee KY, Ito K, Hayashi R, Jazrawi EP, Barnes PJ, and Adcock IM (2006b) NFkappaB and activator protein 1 response elements and the role of histone modifications in IL-1b-induced TGF-b1 gene transcription. J Immunol 176:603-615.
163. Lee KS, Jeong JS, Kim SR, Cho SH, Kolliputi N, Ko YH, Lee KB, Park SC, Park HJ, and Lee YC (2016) Phosphoinositide 3-kinase-d regulates fungus-induced allergic lung inflammation through endoplasmic reticulum stress. Thorax 71:52-63.
164. Lee KS, Lee HK, Hayflick JS, Lee YC, and Puri KD (2006a) Inhibition of phosphoinositide 3-kinase delta attenuates allergic airway inflammation and hyperresponsiveness in murine asthma model. FASEB J 20:455-465.
165. Lee JS, Park SJ, Cho YS, Huh JW, Oh YM, and Lee SD (2015) Role of AMP-activated protein kinase (AMPK) in smoking-Induced lung Inflammation and emphysema. Tuberc Respir Dis (Seoul) 78:8-17.
166. Lemmon MA and Schlessinger J (2010) Cell signaling by receptor tyrosine kinases. Cell 141:1117-1134.
167. Lennartsson J and Rönnstrand L (2012) Stem cell factor receptor/c-Kit: from basic science to clinical implications. Physiol Rev 92:1619-1649.
168. Leung SY, Niimi A, Noble A, Oates T, Williams AS, Medicherla S, Protter AA, and Chung KF (2006) Effect of transforming growth factor-beta receptor I kinase inhibitor 2,4-disubstituted pteridine (SD-208) in chronic allergic airway inflammation and remodeling. J Pharmacol Exp Ther 319:586-594.
169. Levings MK, Bacchetta R, Schulz U, and Roncarolo MG (2002) The role of IL-10 and TGF-beta in the differentiation and effector function of T regulatory cells. Int Arch Allergy Immunol 129:263-276.
170. Li LB, Leung DY, and Goleva E (2015) Activated p38 MAPK in peripheral blood monocytes of steroid resistant asthmatics. PLoS One 10:e0141909.
171. Li N, Li Q, Zhou XD, Kolosov VP, and Perelman JM (2012) Chronic mechanical stress induces mucin 5AC expression in human bronchial epithelial cells through ERK dependent pathways. Mol Biol Rep 39:1019-1028.
172. Lin JH, Zhang JJ, Lin SL, and Chertow GM (2015) Design of a phase 2 clinical trial of an ASK1 inhibitor, GS-4997, in patients with diabetic kidney disease. Nephron 129:29-33.
173. Lomas DA, Lipson DA, Miller BE, Willits L, Keene O, Barnacle H, Barnes NC, and Tal-Singer R; Losmapimod Study Investigators (2012) An oral inhibitor of p38 MAP kinase reduces plasma fibrinogen in patients with chronic obstructive pulmonary disease. J Clin Pharmacol 52:416-424.
174. Lombardi V, Singh AK, and Akbari O (2010) The role of costimulatory molecules in allergic disease and asthma. Int Arch Allergy Immunol 151:179-189.
175. Louie CY, DiMaio MA, Matsukuma KE, Coutre SE, Berry GJ, and Longacre TA (2015) Idelalisib-associated enterocolitis: clinicopathologic features and distinction from other enterocolitides. Am J Surg Pathol 39:1653-1660.
176. Lozano R, Naghavi M, Foreman K, Lim S, Shibuya K, Aboyans V, Abraham J, Adair T, Aggarwal R, and Ahn SY, et al. (2012) Global and regional mortality from 235 causes of death for 20 age groups in 1990 and 2010: a systematic analysis for the Global Burden of Disease Study 2010. Lancet 380:2095-2128.
177. MacNee W, Allan RJ, Jones I, De Salvo MC, and Tan LF (2013) Efficacy and safety of the oral p38 inhibitor PH-797804 in chronic obstructive pulmonary disease: a randomised clinical trial. Thorax 68:738-745.
178. Maneechotesuwan K, Xin Y, Ito K, Jazrawi E, Lee KY, Usmani OS, Barnes PJ, and Adcock IM (2007) Regulation of Th2 cytokine genes by p38 MAPK-mediated phosphorylation of GATA-3. J Immunol 178:2491-2498.
179. Maneechotesuwan K, Yao X, Ito K, Jazrawi E, Usmani OS, Adcock IM, and Barnes PJ (2009) Suppression of GATA-3 nuclear import and phosphorylation: a novel mechanism of corticosteroid action in allergic disease. PLoS Med 6:e1000076.
180. Mannick JB, Del Giudice G, Lattanzi M, Valiante NM, Praestgaard J, Huang B, Lonetto MA, Maecker HT, Kovarik J, and Carson S, et al. (2014) mTOR inhibition improves immune function in the elderly. Sci Transl Med 6:268-179.
181. Manning G, Whyte DB, Martinez R, Hunter T, and Sudarsanam S (2002) The protein kinase complement of the human genome. Science 298:1912-1934.
182. Marks-Konczalik J, Costa M, Robertson J, McKie E, Yang S, and Pascoe S (2015) A post-hoc subgroup analysis of data from a six month clinical trial comparing the efficacy and safety of losmapimod in moderate-severe COPD patients with #2% and.2% blood eosinophils. Respir Med 109:860-869.
183. Martin-Montalvo A, Mercken EM, Mitchell SJ, Palacios HH, Mote PL, Scheibye-Knudsen M, Gomes AP, Ward TM, Minor RK, and Blouin MJ, et al. (2013) Metformin improves healthspan and lifespan in mice. Nat Commun 4:2192.
184. Marwick JA, Caramori G, Casolari P, Mazzoni F, Kirkham PA, Adcock IM, Chung KF, and Papi A (2010a) A role for phosphoinositol 3-kinase delta in the impairment of glucocorticoid responsiveness in patients with chronic obstructive pulmonary disease. J Allergy Clin Immunol 125:1146-1153.
185. Marwick JA, Caramori G, Stevenson CS, Casolari P, Jazrawi E, Barnes PJ, Ito K, Adcock IM, Kirkham PA, and Papi A (2009) Inhibition of PI3Kdelta restores glucocorticoid function in smoking-induced airway inflammation in mice. Am J Respir Crit Care Med 179:542-548.
186. Marwick JA, Chung KF, and Adcock IM (2010b) Phosphatidylinositol 3-kinase isoforms as targets in respiratory disease. Ther Adv Respir Dis 4:19-34.
187. Maslanka T, Otrocka-Domagała I, Zuska-Prot M, Mikiewicz M, Przybysz J, Jasiecka A, and Jaroszewski JJ (2016) IkB kinase b inhibitor, IMD-0354, prevents allergic asthma in a mouse model through inhibition of CD4(+) effector T cell responses in the lung-draining mediastinal lymph nodes. Eur J Pharmacol 775:78-85.
188. Massagué J (2012) TGFb signalling in context. Nat Rev Mol Cell Biol 13:616-630.
189. Matsubara S, Koya T, Takeda K, Joetham A, Miyahara N, Pine P, Masuda ES, Swasey CH, and Gelfand EW (2006a) Syk activation in dendritic cells is essential for airway hyperresponsiveness and inflammation. Am J Respir Cell Mol Biol 34: 426-433.
190. Matsubara S, Li G, Takeda K, Loader JE, Pine P, Masuda ES, Miyahara N, Miyahara S, Lucas JJ, and Dakhama A, et al. (2006b) Inhibition of spleen tyrosine kinase prevents mast cell activation and airway hyperresponsiveness. Am J Respir Crit Care Med 173:56-63.
191. Matsunaga Y, Inoue H, Fukuyama S, Yoshida H, Moriwaki A, Matsumoto T, Matsumoto K, Asai Y, Kubo M, and Yoshimura A, et al. (2011) Effects of a Janus kinase inhibitor, pyridone 6, on airway responses in a murine model of asthma. Biochem Biophys Res Commun 404:261-267.
192. Matthews JG, Irusen E, Chung KF, Barnes PJ, and Adcock IM (1999) p38 Mitogen activated protein kinase mediates IL-2 and IL-4 mediated changes in glucocorticoid receptor affinity. Am J Respir Crit Care Med 157:A336.
193. Mazzi P, Caveggion E, Lapinet-Vera JA, Lowell CA, and Berton G (2015) The Src-Family Kinases Hck and Fgr Regulate Early Lipopolysaccharide-Induced Myeloid Cell Recruitment into the Lung and Their Ability To Secrete Chemokines. J Immunol 195:2383-2395.
194. McMillan DH, Baglole CJ, Thatcher TH, Maggirwar S, Sime PJ, and Phipps RP (2011) Lung-targeted overexpression of the NF-kB member RelB inhibits cigarette smoke-induced inflammation. Am J Pathol 179:125-133.
195. Medicherla S, Fitzgerald M, Spicer D, Woodman P, Ma JY, Kapoun AM, Chakravarty S, Dugar S, Protter AA, and Higgins LS (2007) p38alpha-selective mitogenactivated protein kinase inhibitor SD-282 reduces inflammation in a subchronic model of tobacco smoke-induced airway inflammation. J Pharmacol Exp Ther 324: 921-929.
196. Medina-Tato DA, Ward SG, and Watson ML (2007) Phosphoinositide 3-kinase signalling in lung disease: leucocytes and beyond. Immunology 121:448-461.
197. Meltzer EO, Berkowitz RB, and Grossbard EB (2005) An intranasal Syk-kinase inhibitor (R112) improves the symptoms of seasonal allergic rhinitis in a park environment. J Allergy Clin Immunol 115:791-796.
198. Menet CJ, Rompaey LV, and Geney R (2013) Advances in the discovery of selective JAK inhibitors. Prog Med Chem 52:153-223.
199. Mercado N, Hakim A, Kobayashi Y, Meah S, Usmani OS, Chung KF, Barnes PJ, and Ito K (2012) Restoration of corticosteroid sensitivity by p38 mitogen activated protein kinase inhibition in peripheral blood mononuclear cells from severe asthma. PLoS One 7:e41582.
200. Mercado N, Ito K, and Barnes PJ (2015) Accelerated ageing of the lung in COPD: new concepts. Thorax 70:482-489.
201. Mercado N, To Y, Ito K, and Barnes PJ (2011a) Nortriptyline reverses corticosteroid insensitivity by inhibition of PI3K-d. J Pharmacol Exp Ther 337:465-470.
202. Mercado N, To Y, Kobayashi Y, Adcock IM, Barnes PJ, and Ito K (2011b) p38 mitogen-activated protein kinase-g inhibition by long-acting b2 adrenergic agonists reversed steroid insensitivity in severe asthma. Mol Pharmacol 80: 1128-1135.
203. Millan DS (2011) What is the potential for inhaled p38 inhibitors in the treatment of chronic obstructive pulmonary disease? Future Med Chem 3:1635-1645.
204. Millan DS, Bunnage ME, Burrows JL, Butcher KJ, Dodd PG, Evans TJ, Fairman DA, Hughes SJ, Kilty IC, and Lemaitre A, et al. (2011) Design and synthesis of inhaled p38 inhibitors for the treatment of chronic obstructive pulmonary disease. J Med Chem 54:7797-7814.
205. Minshall EM, Leung DY, Martin RJ, Song YL, Cameron L, Ernst P, and Hamid Q (1997) Eosinophil-associated TGF-beta1 mRNA expression and airways fibrosis in bronchial asthma. Am J Respir Cell Mol Biol 17:326-333.
206. Mitani A, Ito K, Vuppusetty C, Barnes PJ, and Mercado N (2015) Inhibition of mTOR restores corticosteroid sensitivity in chronic obstructive pulmonary disease. Am J Respir Crit Care Med 193:143-153.
207. Mochly-Rosen D, Das K, and Grimes KV (2012) Protein kinase C, an elusive therapeutic target? Nat Rev Drug Discov 11:937-957.
208. Mócsai A, Ruland J, and Tybulewicz VL (2010) The SYK tyrosine kinase: a crucial player in diverse biological functions. Nat Rev Immunol 10:387-402.
209. Moretto N, Bertolini S, Iadicicco C, Marchini G, Kaur M, Volpi G, Patacchini R, Singh D, and Facchinetti F (2012) Cigarette smoke and its component acrolein augment IL-8/CXCL8 mRNA stability via p38 MAPK/MK2 signaling in human pulmonary cells. Am J Physiol Lung Cell Mol Physiol 303:L929-L938.
210. Morphy R (2010) Selectively nonselective kinase inhibition: striking the right balance. J Med Chem 53:1413-1437.
211. Moy LY, Jia Y, Caniga M, Lieber G, Gil M, Fernandez X, Sirkowski E, Miller R, Alexander JP, and Lee HH, et al. (2013) Inhibition of spleen tyrosine kinase attenuates allergen-mediated airway constriction. Am J Respir Cell Mol Biol 49: 1085-1092.
212. Mushaben EM, Brandt EB, Hershey GK, and Le Cras TD (2013) Differential effects of rapamycin and dexamethasone in mouse models of established allergic asthma. PLoS One 8:e54426.
213. Myou S, Leff AR, Myo S, Boetticher E, Tong J, Meliton AY, Liu J, Munoz NM, and Zhu X (2003) Blockade of inflammation and airway hyperresponsiveness in immune-sensitized mice by dominant-negative phosphoinositide 3-kinase-TAT. J Exp Med 198:1573-1582.
214. Nadel JA and Burgel PR (2001) The role of epidermal growth factor in mucus production. Curr Opin Pharmacol 1:254-258.
215. Nakamaru Y, Vuppusetty C, Wada H, Milne JC, Ito M, Rossios C, Elliot M, Hogg J, Kharitonov S, and Goto H, et al. (2009) A protein deacetylase SIRT1 is a negative regulator of metalloproteinase-9. FASEB J 23:2810-2819.
216. Nashed BF, Zhang T, Al-Alwan M, Srinivasan G, Halayko AJ, Okkenhaug K, Vanhaesebroeck B, Hayglass KT, and Marshall AJ (2007) Role of the phosphoinositide 3-kinase p110delta in generation of type 2 cytokine responses and allergic airway inflammation. Eur J Immunol 37:416-424.
217. Nath P, Eynott P, Leung SY, Adcock IM, Bennett BL, and Chung KF (2005) Potential role of c-Jun NH2-terminal kinase in allergic airway inflammation and remodelling: effects of SP600125. Eur J Pharmacol 506:273-283.
218. Nath P, Leung SY, Williams A, Noble A, Chakravarty SD, Luedtke GR, Medicherla S, Higgins LS, Protter A, and Chung KF (2006) Importance of p38 mitogen-activated protein kinase pathway in allergic airway remodelling and bronchial hyperresponsiveness. Eur J Pharmacol 544:160-167.
219. Newton R, Holden NS, Catley MC, Oyelusi W, Leigh R, Proud D, and Barnes PJ (2007) Repression of inflammatory gene expression in human pulmonary epithelial cells by small-molecule IkappaB kinase inhibitors. J Pharmacol Exp Ther 321: 734-742.
220. Ngkelo A, Hoffmann RF, Durham AL, Marwick JA, Brandenburg SM, de Bruin HG, Jonker MR, Rossios C, Tsitsiou E, and Caramori G, et al. (2015) Glycogen synthase kinase-3b modulation of glucocorticoid responsiveness in COPD. Am J Physiol Lung Cell Mol Physiol 309:L1112-L1123.
221. Nijjar JS, Tindell A, McInnes IB, and Siebert S (2013) Inhibition of spleen tyrosine kinase in the treatment of rheumatoid arthritis. Rheumatology (Oxford) 52: 1556-1562.
222. Norman P (2014a) Respivert’s multikinase inhibitors, an evaluation of WO2014033446 to WO2014033449. Expert Opin Ther Pat 24:1397-1407.
223. Norman P (2014b) Spleen tyrosine kinase inhibitors: a review of the patent literature 2010-2013. Expert Opin Ther Pat 24:573-595.
224. Norman P (2015) Investigational p38 inhibitors for the treatment of chronic obstructive pulmonary disease. Expert Opin Investig Drugs 24:383-392.
225. Norman RA, Schott AK, Andrews DM, Breed J, Foote KM, Garner AP, Ogg D, Orme JP, Pink JH, and Roberts K, et al. (2012a) Protein-ligand crystal structures can guide the design of selective inhibitors of the FGFR tyrosine kinase. J Med Chem 55:5003-5012.
226. Norman RA, Toader D, and Ferguson AD (2012b) Structural approaches to obtain kinase selectivity. Trends Pharmacol Sci 33:273-278.
227. Onions ST, Ito K, Charron CE, Brown RJ, Colucci M, Frickel F, Hardy G, Joly K, King-Underwood J, and Kizawa Y, et al. (2016) Discovery of narrow spectrum kinase inhibitors: new therapeutic agents for the treatment of COPD and steroidresistant asthma. J Med Chem 59:1727-1746.
228. O’Shea JJ, Schwartz DM, Villarino AV, Gadina M, McInnes IB, and Laurence A (2015) The JAK-STAT pathway: impact on human disease and therapeutic intervention. Annu Rev Med 66:311-328.
229. Papi A, Contoli M, Adcock IM, Bellettato C, Padovani A, Casolari P, Stanciu LA, Barnes PJ, Johnston SL, and Ito K, et al. (2013) Rhinovirus infection causes steroid resistance in airway epithelium through nuclear factor kB and c-Jun N-terminal kinase activation. J Allergy Clin Immunol 132:1075-1085.e6.
230. Paredi P and Barnes PJ (2009) The airway vasculature: recent advances and clinical implications. Thorax 64:444-450.
231. Park CS, Bang BR, Kwon HS, Moon KA, Kim TB, Lee KY, Moon HB, and Cho YS (2012) Metformin reduces airway inflammation and remodeling via activation of AMP-activated protein kinase. Biochem Pharmacol 84:1660-1670.
232. Partridge MR, van der Molen T, Myrseth SE, and Busse WW (2006) Attitudes and actions of asthma patients on regular maintenance therapy: the INSPIRE study. BMC Pulm Med 6:13.
233. Paschalaki KE, Starke RD, Hu Y, Mercado N, Margariti A, Gorgoulis VG, Randi AM, and Barnes PJ (2013) Dysfunction of endothelial progenitor cells from smokers and COPD patients due to increased DNA damage and senescence. Stem Cells 31: 2813-2826.
234. Penton PC, Wang X, Amatullah H, Cooper J, Godri K, North ML, Khanna N, Scott JA, and Chow CW (2013) Spleen tyrosine kinase inhibition attenuates airway hyperresponsiveness and pollution-induced enhanced airway response in a chronic mouse model of asthma. J Clin Immunol 131:512-520.
235. Pera T, Atmaj C, van der Vegt M, Halayko AJ, Zaagsma J, and Meurs H (2012) Role for TAK1 in cigarette smoke-induced proinflammatory signaling and IL-8 release by human airway smooth muscle cells. Am J Physiol Lung Cell Mol Physiol 303: L272-L278.
236. Pera T, Sami R, Zaagsma J, and Meurs H (2011) TAK1 plays a major role in growth factor-induced phenotypic modulation of airway smooth muscle. Am J Physiol Lung Cell Mol Physiol 301:L822-L828.
237. Pernis AB and Rothman PB (2002) JAK-STAT signaling in asthma. J Clin Invest 109:1279-1283.
238. Poh AR, O’Donoghue RJ, and Ernst M (2015) Hematopoietic cell kinase (HCK) as a therapeutic target in immune and cancer cells. Oncotarget 6:15752-15771.
239. Possa SS, Charafeddine HT, Righetti RF, da Silva PA, Almeida-Reis R, Saraiva-Romanholo BM, Perini A, Prado CM, Leick-Maldonado EA, and Martins MA, et al. (2012) Rho-kinase inhibition attenuates airway responsiveness, inflammation, matrix remodeling, and oxidative stress activation induced by chronic inflammation. Am J Physiol Lung Cell Mol Physiol 303:L939-L952.
240. Postma DS and Rabe KF (2015) The Asthma-COPD Overlap Syndrome. N Engl J Med 373:1241-1249.
241. Rajendrasozhan S, Yang SR, Kinnula VL, and Rahman I (2008) SIRT1, an antiinflammatory and antiaging protein, is decreased in lungs of patients with chronic obstructive pulmonary disease. Am J Respir Crit Care Med 177:861-870.
242. Ramis I, Calama E, Domènech A, Carreño C, Calaf E, Cordoba M, Alberti J, De Alba J, Bach J, and Prats N, et al. (2014) New inhaled JAK inhibitor LAS194046 inhibits allergen-induced airway inflammation in Brown Norway rats. Eur Respir J 44 (Suppl 58):P1508.
243. Ramis I, Otal R, Carreño C, Domènech A, Eichhorn P, Orellana A, Maldonado M, De Alba J, Prats N, and Fernández JC, et al. (2015) A novel inhaled Syk inhibitor blocks mast cell degranulation and early asthmatic response. Pharmacol Res 99: 116-124.
244. Randhawa V and Bagler G (2012) Identification of SRC as a potent drug target for asthma, using an integrative approach of protein interactome analysis and in silico drug discovery. OMICS 16:513-526.
245. Rastrick JM, Stevenson CS, Eltom S, Grace M, Davies M, Kilty I, Evans SM, Pasparakis M, Catley MC, and Lawrence T, et al. (2013) Cigarette smoke induced airway inflammation is independent of NF-kB signalling. PLoS One 8:e54128.
246. Reber L, Da Silva CA, and Frossard N (2006) Stem cell factor and its receptor c-Kit as targets for inflammatory diseases. Eur J Pharmacol 533:327-340.
247. Renda T, Baraldo S, Pelaia G, Bazzan E, Turato G, Papi A, Maestrelli P, Maselli R, Vatrella A, and Fabbri LM, et al. (2008) Increased activation of p38 MAPK in COPD. Eur Respir J 31:62-69.
248. Riccaboni M, Bianchi I, and Petrillo P (2010) Spleen tyrosine kinases: biology, therapeutic targets and drugs. Drug Discov Today 15:517-530.
249. Riento K and Ridley AJ (2003) Rocks: multifunctional kinases in cell behaviour. Nat Rev Mol Cell Biol 4:446-456.
250. Righetti RF, Pigati PA, Possa SS, Habrum FC, Xisto DG, Antunes MA, Leick EA, Prado CM, Martins MdeA, and Rocco PR, et al. (2014) Effects of Rho-kinase inhibition in lung tissue with chronic inflammation. Respir Physiol Neurobiol 192: 134-146.
251. Robert V, Triffaux E, Paulet PE, Guéry JC, Pelletier L, and Savignac M (2014) Protein kinase C-dependent activation of CaV1.2 channels selectively controls human TH2-lymphocyte functions. J Allergy Clin Immunol 133:1175-1183.
252. Roskoski R Jr (2015) Src protein-tyrosine kinase structure, mechanism, and small molecule inhibitors. Pharmacol Res 94:9-25.
253. Rosse C, Linch M, Kermorgant S, Cameron AJ, Boeckeler K, and Parker PJ (2010) PKC and the control of localized signal dynamics. Nat Rev Mol Cell Biol 11: 103-112.
254. Rossetti M, Savineau JP, Crevel H, and Marthan R (1995) Role of protein kinase C in nonsensitized and passively sensitized human isolated bronchial smooth muscle. Am J Physiol 268:L966-L971.
255. Rückle T, Schwarz MK, and Rommel C (2006) PI3Kgamma inhibition: towards an ‘aspirin of the 21st century’? Nat Rev Drug Discov 5:903-918.
256. Russell P, Cass L, and Ito K (2013) Russell P, Cass L, Ito K, Safety, pharmacokinetic and pharmacodynamic profile of RV568, a narrow spectrum kinase inhibitor, following repeat inhaled dosing in COPD patients. Eur Resp J 2013;42:1371. Eur Respir J 42:1371.
257. Ruwanpura SM, McLeod L, Miller A, Jones J, Vlahos R, Ramm G, Longano A, Bardin PG, Bozinovski S, and Anderson GP, et al. (2012) Deregulated Stat3 signaling dissociates pulmonary inflammation from emphysema in gp130 mutant mice. Am J Physiol Lung Cell Mol Physiol 302:L627-L639.
258. Saccani S, Pantano S, and Natoli G (2002) p38-Dependent marking of inflammatory genes for increased NF-k B recruitment. Nat Immunol 3:69-75.
259. Salt IP and Palmer TM (2012) Exploiting the anti-inflammatory effects of AMPactivated protein kinase activation. Expert Opin Investig Drugs 21:1155-1167.
260. Sapey E, Greenwood H, Walton G, Mann E, Love A, Aaronson N, Insall RH, Stockley RA, and Lord JM (2014) Phosphoinositide 3-kinase inhibition restores neutrophil accuracy in the elderly: toward targeted treatments for immunosenescence. Blood 123:239-248.
261. Sato S, Sanjo H, Takeda K, Ninomiya-Tsuji J, Yamamoto M, Kawai T, Matsumoto K, Takeuchi O, and Akira S (2005) Essential function for the kinase TAK1 in innate and adaptive immune responses. Nat Immunol 6:1087-1095.
262. Scanlon ST and McKenzie AN (2012) Type 2 innate lymphoid cells: new players in asthma and allergy. Curr Opin Immunol 24:707-712.
263. Scarpulla RC (2011) Metabolic control of mitochondrial biogenesis through the PGC-1 family regulatory network. Biochim Biophys Acta 1813:1269-1278.
264. Schaafsma D, Bos IS, Zuidhof AB, Zaagsma J, and Meurs H (2008a) The inhaled Rho kinase inhibitor Y-27632 protects against allergen-induced acute bronchoconstriction, airway hyperresponsiveness, and inflammation. Am J Physiol Lung Cell Mol Physiol 295:L214-L219.
265. Schaafsma D, Gosens R, Zaagsma J, Halayko AJ, and Meurs H (2008b) Rho kinase inhibitors: a novel therapeutical intervention in asthma? Eur J Pharmacol 585: 398-406.
266. Schlapbach A and Huppertz C (2009) Low-molecular-weight MK2 inhibitors: a tough nut to crack! Future Med Chem 1:1243-1257.
267. Schwartz DM, Bonelli M, Gadina M, and O’Shea JJ (2016) Type I/II cytokines, JAKs, and new strategies for treating autoimmune diseases. Nat Rev Rheumatol 12: 25-36.
268. Schwartz S, Wongvipat J, Trigwell CB, Hancox U, Carver BS, Rodrik-Outmezguine V, Will M, Yellen P, de Stanchina E, and Baselga J, et al. (2015) Feedback suppression of PI3Ka signaling in PTEN-mutated tumors is relieved by selective inhibition of PI3Kb. Cancer Cell 27:109-122.
269. Shaifta Y, Irechukwu N, Prieto-Lloret J, MacKay CE, Marchon KA, Ward JP, and Knock GA (2015) Divergent modulation of Rho-kinase and Ca(2+) influx pathways by Src family kinases and focal adhesion kinase in airway smooth muscle. Br J Pharmacol 172:5265-5280.
270. Shao MX and Nadel JA (2005) Neutrophil elastase induces MUC5AC mucin production in human airway epithelial cells via a cascade involving protein kinase C, reactive oxygen species, and TNF-alpha-converting enzyme. J Immunol 175: 4009-4016.
271. Shen H, Yoshida H, Yan F, Li W, Xu F, Huang H, Jono H, and Li JD (2008) Synergistic induction of MUC5AC mucin by nontypeable Haemophilus influenzae and Streptococcus pneumoniae. Biochem Biophys Res Commun 365:795-800.
272. Shigeta A, Tada Y, Wang JY, Ishizaki S, Tsuyusaki J, Yamauchi K, Kasahara Y, Iesato K, Tanabe N, and Takiguchi Y, et al. (2012) CD40 amplifies Fas-mediated apoptosis: a mechanism contributing to emphysema. Am J Physiol Lung Cell Mol Physiol 303:L141-L151.
273. Shinkai M, López-Boado YS, and Rubin BK (2007) Clarithromycin has an immunomodulatory effect on ERK-mediated inflammation induced by Pseudomonas aeruginosa flagellin. J Antimicrob Chemother 59:1096-1101.
274. Shuto T, Xu H, Wang B, Han J, Kai H, Gu XX, Murphy TF, Lim DJ, and Li JD (2001) Activation of NF-kappa B by nontypeable Hemophilus influenzae is mediated by toll-like receptor 2-TAK1-dependent NIK-IKK alpha /beta-I kappa B alpha and MKK3/6-p38 MAP kinase signaling pathways in epithelial cells. Proc Natl Acad Sci USA 98:8774-8779.
275. Simeone-Penney MC, Severgnini M, Rozo L, Takahashi S, Cochran BH, and Simon AR (2008) PDGF-induced human airway smooth muscle cell proliferation requires STAT3 and the small GTPase Rac1. Am J Physiol Lung Cell Mol Physiol 294: L698-L704.
276. Singh D, Siew L, Christensen J, Plumb J, Clarke GW, Greenaway S, Perros-Huguet C, Clarke N, Kilty I, and Tan L (2015) Oral and inhaled p38 MAPK inhibitors: effects on inhaled LPS challenge in healthy subjects. Eur J Clin Pharmacol 71: 1175-1184.
277. Singh D, Smyth L, Borrill Z, Sweeney L, and Tal-Singer R (2010) A randomized, placebo-controlled study of the effects of the p38 MAPK inhibitor SB-681323 on blood biomarkers of inflammation in COPD patients. J Clin Pharmacol 50:94-100.
278. Smith SJ, Fenwick PS, Nicholson AG, Kirschenbaum F, Finney-Hayward TK, Higgins LS, Giembycz MA, Barnes PJ, and Donnelly LE (2006) Inhibitory effect of p38 mitogen-activated protein kinase inhibitors on cytokine release from human macrophages. Br J Pharmacol 149:393-404.
279. Sommers CD, Thompson JM, Guzova JA, Bonar SL, Rader RK, Mathialagan S, Venkatraman N, Holway VW, Kahn LE, and Hu G, et al. (2009) Novel tightbinding inhibitory factor-kappaB kinase (IKK-2) inhibitors demonstrate targetspecific anti-inflammatory activities in cellular assays and following oral and local delivery in an in vivo model of airway inflammation. J Pharmacol Exp Ther 330: 377-388.
280. Song MS, Salmena L, and Pandolfi PP (2012) The functions and regulation of the PTEN tumour suppressor. Nat Rev Mol Cell Biol 13:283-296.
281. Springer J, Scholz FR, Peiser C, Groneberg DA, and Fischer A (2004) SMADsignaling in chronic obstructive pulmonary disease: transcriptional downregulation of inhibitory SMAD 6 and 7 by cigarette smoke. Biol Chem 385:649-653.
282. Starosyla SA, Volynets GP, Lukashov SS, Gorbatiuk OB, Golub AG, Bdzhola VG, and Yarmoluk SM (2015) Identification of apoptosis signal-regulating kinase 1 (ASK1) inhibitors among the derivatives of benzothiazol-2-yl-3-hydroxy-5-phenyl-1,5-dihydro-pyrrol-2-one. Bioorg Med Chem 23:2489-2497.
283. Steinberg GR and Kemp BE (2009) AMPK in health and disease. Physiol Rev 89: 1025-1078.
284. Stenton GR, Kim MK, Nohara O, Chen CF, Hirji N, Wills FL, Gilchrist M, Hwang PH, Park JG, and Finlay W, et al. (2000) Aerosolized Syk antisense suppresses Syk expression, mediator release from macrophages, and pulmonary inflammation. J Immunol 164:3790-3797.
285. Stenton GR, Mackenzie LF, Tam P, Cross JL, Harwig C, Raymond J, Toews J, Chernoff D, MacRury T, and Szabo C (2013a) Characterization of AQX-1125, a small-molecule SHIP1 activator: Part 2. Efficacy studies in allergic and pulmonary inflammation models in vivo. Br J Pharmacol 168:1519-1529.
286. Stenton GR, Mackenzie LF, Tam P, Cross JL, Harwig C, Raymond J, Toews J, Wu J, Ogden N, and MacRury T, et al. (2013b) Characterization of AQX-1125, a smallmolecule SHIP1 activator: Part 1. Effects on inflammatory cell activation and chemotaxis in vitro and pharmacokinetic characterization in vivo. Br J Pharmacol 168:1506-1518.
287. Stenton GR, Ulanova M, Déry RE, Merani S, Kim MK, Gilchrist M, Puttagunta L, Musat-Marcu S, James D, and Schreiber AD, et al. (2002) Inhibition of allergic inflammation in the airways using aerosolized antisense to Syk kinase. J Immunol 169:1028-1036.
288. Sugita A, Ogawa H, Azuma M, Muto S, Honjo A, Yanagawa H, Nishioka Y, Tani K, Itai A, and Sone S (2009) Antiallergic and anti-inflammatory effects of a novel I kappaB kinase beta inhibitor, IMD-0354, in a mouse model of allergic inflammation. Int Arch Allergy Immunol 148:186-198.
289. Sun L, Deng L, Ea CK, Xia ZP, and Chen ZJ (2004) The TRAF6 ubiquitin ligase and TAK1 kinase mediate IKK activation by BCL10 and MALT1 in T lymphocytes. Mol Cell 14:289-301.
290. Sun SC (2012) The noncanonical NF-kB pathway. Immunol Rev 246:125-140.
291. Suzuki J, Ogawa M, Muto S, Itai A, Isobe M, Hirata Y, and Nagai R (2011) Novel IkB kinase inhibitors for treatment of nuclear factor-kB-related diseases. Expert Opin Investig Drugs 20:395-405.
292. Szatmáry Z, Garabedian MJ, and Vilcek J (2004) Inhibition of glucocorticoid receptor-mediated transcriptional activation by p38 mitogen-activated protein (MAP) kinase. J Biol Chem 279:43708-43715.
293. Takahashi-Yanaga F (2013) Activator or inhibitor? GSK-3 as a new drug target. Biochem Pharmacol 86:191-199.
294. Takeyama K, Dabbagh K, Jeong Shim J, Dao-Pick T, Ueki IF, and Nadel JA (2000) Oxidative stress causes mucin synthesis via transactivation of epidermal growth factor receptor: role of neutrophils. J Immunol 164:1546-1552.
295. Takeyama K, Jung B, Shim JJ, Burgel PR, Dao-Pick T, Ueki IF, Protin U, Kroschel P, and Nadel JA (2001) Activation of epidermal growth factor receptors is responsible for mucin synthesis induced by cigarette smoke. Am J Physiol Lung Cell Mol Physiol 280:L165-L172.
296. Takezawa K, Ogawa T, Shimizu S, and Shimizu T (2016) Epidermal growth factor receptor inhibitor AG1478 inhibits mucus hypersecretion in airway epithelium. Am J Rhinol Allergy 30:1-6.
297. Takizawa H, Tanaka M, Takami K, Ohtoshi T, Ito K, Satoh M, Okada Y, Yamasawa F, Nakahara K, and Umeda A (2001) Increased expression of transforming growth factor-beta1 in small airway epithelium from tobacco smokers and patients with chronic obstructive pulmonary disease (COPD). Am J Respir Crit Care Med 163: 1476-1483.
298. Taraseviciene-Stewart L, Douglas IS, Nana-Sinkam PS, Lee JD, Tuder RM, Nicolls MR, and Voelkel NF (2006) Is alveolar destruction and emphysema in chronic obstructive pulmonary disease an immune disease? Proc Am Thorac Soc 3: 687-690.
299. Thomas MJ, Smith A, Head DH, Milne L, Nicholls A, Pearce W, Vanhaesebroeck B, Wymann MP, Hirsch E, and Trifilieff A, et al. (2005) Airway inflammation: chemokine-induced neutrophilia and the class I phosphoinositide 3-kinases. Eur J Immunol 35:1283-1291.
300. Thorarensen A and Kaila N (2014) New spleen tyrosine kinase inhibitors: patent applications published during 2011-2013. Pharm Pat Anal 3:523-541.
301. To Y, Ito K, Kizawa Y, Failla M, Ito M, Kusama T, Elliot M, Hogg JC, Adcock IM, and Barnes PJ (2010) Targeting phosphoinositide-3-kinase-delta with theophylline reverses corticosteroid insensitivity in chronic obstructive pulmonary disease. Am J Respir Crit Care Med 182:897-904.
302. Trempolec N, Dave-Coll N, and Nebreda AR (2013) SnapShot: p38 MAPK substrates. Cell 152:924-924.e1.
303. Tudhope SJ, Catley MC, Fenwick PS, Russell RE, Rumsey WL, Newton R, Barnes PJ, and Donnelly LE (2007) The role of IkappaB kinase 2, but not activation of NF-kappaB, in the release of CXCR3 ligands from IFN-g-stimulated human bronchial epithelial cells. J Immunol 179:6237-6245.
304. Tudhope SJ, Finney-Hayward TK, Nicholson AG, Mayer RJ, Barnette MS, Barnes PJ, and Donnelly LE (2008) Different mitogen-activated protein kinase-dependent cytokine responses in cells of the monocyte lineage. J Pharmacol Exp Ther 324: 306-312.
305. van der Velden JL, Hoffman SM, Alcorn JF, Tully JE, Chapman DG, Lahue KG, Guala AS, Lundblad LK, Aliyeva M, and Daphtary N, et al. (2014) Absence of c-Jun NH2-terminal kinase 1 protects against house dust mite-induced pulmonary remodeling but not airway hyperresponsiveness and inflammation. Am J Physiol Lung Cell Mol Physiol 306:L866-L875.
306. Vanhaesebroeck B and Khwaja A (2014) PI3Kd inhibition hits a sensitive spot in B cell malignancies. Cancer Cell 25:269-271.
307. Vanhaesebroeck B, Stephens L, and Hawkins P (2012) PI3K signalling: the path to discovery and understanding. Nat Rev Mol Cell Biol 13:195-203.
308. Vanhaesebroeck B, Whitehead MA, and Piñeiro R (2016) Molecules in medicine minireview: isoforms of PI3K in biology and disease. J Mol Med (Berl) 94:5-11.
309. von Mehren M (2006) Beyond imatinib: second generation c-KIT inhibitors for the management of gastrointestinal stromal tumors. Clin Colorectal Cancer 6 (Suppl 1):S30-S34.
310. Wang D, Boerner SA, Winkler JD, and LoRusso PM (2007) Clinical experience of MEK inhibitors in cancer therapy. Biochim Biophys Acta 1773:1248-1255.
311. Wang B, Cleary PP, Xu H, and Li JD (2003) Up-regulation of interleukin-8 by novel small cytoplasmic molecules of nontypeable Haemophilus influenzae via p38 and extracellular signal-regulated kinase pathways. Infect Immun 71:5523-5530.
312. Wang X, Khanna N, Wu J, Godri Pollitt K, Evans GJ, Chow CW, and Scott JA (2015) Syk mediates airway contractility independent of leukocyte function. Allergy 70: 429-435.
313. Wang IM, Stepaniants S, Boie Y, Mortimer JR, Kennedy B, Elliott M, Hayashi S, Loy L, Coulter S, and Cervino S, et al. (2008) Gene expression profiling in patients with chronic obstructive pulmonary disease and lung cancer. Am J Respir Crit Care Med 177:402-411.
314. Wang Z, Wesche H, Stevens T, Walker N, and Yeh WC (2009) IRAK-4 inhibitors for inflammation. Curr Top Med Chem 9:724-737.
315. Watz H, Barnacle H, Hartley BF, and Chan R (2014) Efficacy and safety of the p38 MAPK inhibitor losmapimod for patients with chronic obstructive pulmonary disease: a randomised, double-blind, placebo-controlled trial. Lancet Respir Med 2: 63-72.
316. Webb BJL, Lindsay MA, Barnes PJ, and Giembycz MA (1997). Protein kinase C isoenzymes in airway smooth muscle. Biochem J 324:167-175.
317. Wiegman CH, Russell KE, Sieffert J, Rossios C, Adcock IM, Rothaul A, Main M, and Morgan F (2015) Rhe selective pan-Janus kinase (JAK) inhibitor VR588 demonstrates potent anti-inflammatory activity in a murne chronic house dust mite model. Am J Respir Crit Care Med 191:A6435.
318. Wilkinson JE, Burmeister L, Brooks SV, Chan CC, Friedline S, Harrison DE, Hejtmancik JF, Nadon N, Strong R, and Wood LK, et al. (2012) Rapamycin slows aging in mice. Aging Cell 11:675-682.
319. Williams AS, Issa R, Durham A, Leung SY, Kapoun A, Medicherla S, Higgins LS, Adcock IM, and Chung KF (2008) Role of p38 mitogen-activated protein kinase in ozone-induced airway hyperresponsiveness and inflammation. Eur J Pharmacol 600:117-122.
320. Wilson R, Cahn AAD, McSherry L, Rambaran C, Sousa A, and Wilbraham D (2013) Safety, tolerability and pharmacokinetics (PK) of single and repeat nebulised doses of a novel phosphoinositide 3-kinase d inhibitor (PI3Kd), GSK2269557, administered to healthy male subjects in a phase I study. Eur Respir J 42 (Suppl 57): P729.
321. Winkler DG, Faia KL, DiNitto JP, Ali JA, White KF, Brophy EE, Pink MM, Proctor JL, Lussier J, and Martin CM, et al. (2013) PI3K-d and PI3K-g inhibition by IPI-145 abrogates immune responses and suppresses activity in autoimmune and inflammatory disease models. Chem Biol 20:1364-1374.
322. Woodruff PG, Wolff M, Hohlfeld JM, Krug N, Dransfield MT, Sutherland ER, Criner GJ, Kim V, Prasse A, and Nivens MC, et al. (2010) Safety and efficacy of an inhaled epidermal growth factor receptor inhibitor (BIBW 2948 BS) in chronic obstructive pulmonary disease. Am J Respir Crit Care Med 181:438-445.
323. Worby CA and Dixon JE (2014) PTEN. Annu Rev Biochem 83:641-669.
324. Wu P, Clausen MH, and Nielsen TE (2015b) Allosteric small-molecule kinase inhibitors. Pharmacol Ther 156:59-68.
325. Wu HM, Fang L, Shen QY, and Liu RY (2015a) SP600125 promotes resolution of allergic airway inflammation via TLR9 in an OVA-induced murine acute asthma model. Mol Immunol 67 (2 Pt B):311-316.
326. Wu P, Nielsen TE, and Clausen MH (2015c) FDA-approved small-molecule kinase inhibitors. Trends Pharmacol Sci 36:422-439.
327. Wu W, Wang T, Dong JJ, Liao ZL, and Wen FQ (2012) Silencing of c-kit with small interference RNA attenuates inflammation in a murine model of allergic asthma. Int J Mol Med 30:63-68.
328. Xie S, Sukkar MB, Issa R, Khorasani NM, and Chung KF (2007) Mechanisms of induction of airway smooth muscle hyperplasia by transforming growth factorbeta. Am J Physiol Lung Cell Mol Physiol 293:L245-L253.
329. Yahiaoui L, Villeneuve A, Valderrama-Carvajal H, Burke F, and Fixman ED (2006) Endothelin-1 regulates proliferative responses, both alone and synergistically with PDGF, in rat tracheal smooth muscle cells. Cell Physiol Biochem 17:37-46.
330. Yamamoto N, Takeshita K, Shichijo M, Kokubo T, Sato M, Nakashima K, Ishimori M, Nagai H, Li YF, and Yura T, et al. (2003) The orally available spleen tyrosine kinase inhibitor 2-[7-(3,4-dimethoxyphenyl)-imidazo[1,2-c]pyrimidin-5-ylamino]nicotinamide dihydrochloride (BAY 61-3606) blocks antigeninduced airway inflammation in rodents. J Pharmacol Exp Ther 306: 1174-1181.
331. Yanagisawa S, Sugiura H, Yokoyama T, Yamagata T, Ichikawa T, Akamatsu K, Koarai A, Hirano T, Nakanishi M, and Matsunaga K, et al. (2009) The possible role of hematopoietic cell kinase in the pathophysiology of COPD. Chest 135: 94-101.
332. Yang F, Oz HS, Barve S, de Villiers WJ, McClain CJ, and Varilek GW (2001) The green tea polyphenol (-)-epigallocatechin-3-gallate blocks nuclear factor-kappa B activation by inhibiting I kappa B kinase activity in the intestinal epithelial cell line IEC-6. Mol Pharmacol 60:528-533.
333. Yew-Booth L, Birrell MA, Lau MS, Baker K, Jones V, Kilty I, and Belvisi MG (2015) JAK-STAT pathway activation in COPD. Eur Respir J 46:843-845.
334. Yu Q and Stamenkovic I (2000) Cell surface-localized matrix metalloproteinase-9 proteolytically activates TGF-beta and promotes tumor invasion and angiogenesis. Genes Dev 14:163-176.
335. Yum HY, Cho JY, Miller M, and Broide DH (2011) Allergen-induced coexpression of bFGF and TGF-b1 by macrophages in a mouse model of airway remodeling: bFGF induces macrophage TGF-b1 expression in vitro. Int Arch Allergy Immunol 155: 12-22.
336. Ziegelbauer K, Gantner F, Lukacs NW, Berlin A, Fuchikami K, Niki T, Sakai K, Inbe H, Takeshita K, and Ishimori M, et al. (2005) A selective novel low-molecularweight inhibitor of IkappaB kinase-beta (IKK-beta) prevents pulmonary inflammation and shows broad anti-inflammatory activity. Br J Pharmacol 145: 178-192.